PX1 Research supplies USA-manufactured, HPLC-verified Bronchogen (Ala-Asp-Glu-Leu) for advanced preclinical studies evaluating bronchial tissue signaling and airway hyperresponsiveness. Every research-grade lot undergoes rigorous ISO 17025 analytical testing and endotoxin screening to ensure absolute batch-to-batch consistency for in vitro and animal models.
PX1 Research supplies USA-manufactured, HPLC-verified Bronchogen (Ala-Asp-Glu-Leu) for advanced preclinical studies evaluating bronchial tissue signaling and airway hyperresponsiveness. Every research-grade lot undergoes rigorous ISO 17025 analytical testing and endotoxin screening to ensure absolute batch-to-batch consistency for in vitro and animal models.
A professional manufacturer of research-grade Bronchogen for airway hyperresponsiveness studies provides high-purity, synthetic Ala-Asp-Glu-Leu tetrapeptide produced under strict GMP-compliant quality controls. PX1 Research delivers USA-manufactured Bronchogen verified by RP-HPLC and ESI-MS with lot-specific Certificates of Analysis (COAs), guaranteeing low endotoxin levels and verified structural identity for rigorous in vitro and animal research applications.
Airway hyperresponsiveness (AHR) represents a complex physiological state characterized by an exaggerated bronchoconstrictor response to allergen or chemical challenge. Investigating the molecular cascades governing bronchial smooth muscle constriction, epithelial barrier integrity, and local cytokine signaling requires research compounds of uncompromised purity. When evaluating a bronchogen airway hyperresponsiveness professional manufacturer, investigators must prioritize analytical transparency, strict endotoxin controls, and documented batch reproducibility to eliminate confounding variables in preclinical assays.
PX1 Research serves academic institutions, biotechnology firms, and contract research organizations (CROs) by manufacturing short-chain regulatory peptides formulated strictly for laboratory investigation. By maintaining domestic synthesis facilities in California and Arizona, PX1 ensures complete chain-of-custody oversight and immediate dispatch of stability-controlled research reagents.
Bronchogen is a synthetic short peptide composed of four amino acid residues: L-alanyl-L-alpha-aspartyl-L-alpha-glutamyl-L-leucine (Sequence: H-Ala-Asp-Glu-Leu-OH; CAS No. 343306-79-6). Belonging to the class of short peptide bioregulators initially conceptualized in Khavinson's peptide research, Bronchogen was designed to mimic endogenous signaling fragments that interact with chromatin structures within respiratory tissue.
At the cellular level, short peptides containing acidic amino acid motifs (such as Asp and Glu) possess the ability to penetrate cellular and nuclear membranes. In vitro studies demonstrate that these peptide sequences bind to specific nucleosome promoter regions, promoting epigenetically active chromatin remodeling. Preclinical models indicate that this interaction regulates transcription factors associated with cytoprotective proteins, antioxidant enzymes, and cell-adhesion molecules within bronchial epithelial cells.
In cell culture models of bronchial tissue, Bronchogen administration has been observed to modulate the expression of heat shock proteins and cytokeratins. This localized transcriptional regulation is hypothesized to support structural integrity within respiratory tissues exposed to inflammatory stress, providing a focused framework for investigating short-chain bioregulatory peptides in pulmonary biology.
Airway hyperresponsiveness typically involves an imbalance between pro-inflammatory Th2 signaling cascades and anti-inflammatory counter-regulatory mechanisms. In rodent models of allergic airway inflammation (such as ovalbumin-sensitized mice or rats), preclinical research suggests that short peptide bioregulators like Bronchogen modulate the local inflammatory infiltrate. Specifically, animal studies indicate a reduction in bronchoalveolar lavage fluid (BALF) eosinophil counts and a corresponding decrease in key Th2 cytokines, including interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13).
Furthermore, in vitro assays using primary human bronchial epithelial cells (HBECs) demonstrate that Bronchogen exposure reduces baseline oxidative stress markers and mitigates hydrogen peroxide-induced cellular damage. By blunting reactive oxygen species (ROS) accumulation, the compound helps maintain tight junction protein expression (such as ZO-1 and occludin), thereby preserving epithelial barrier function under challenge conditions.
Preclinical evaluation of airway resistance via plethysmography in animal models indicates that pre-treatment with synthetic Bronchogen attenuates methacholine-induced bronchoconstriction. Researchers utilize these findings to explore how targeted peptide sequences influence smooth muscle hyper-reactivity, extracellular matrix remodeling, and chronic tissue remodeling pathways in respiratory pathology.
To contextualize Bronchogen within pulmonary and immunological research, it is useful to evaluate its structural and functional properties alongside other short synthetic peptides. While Bronchogen specifically targets respiratory tissue transcription, related bioregulators interact with complementary physiological systems.
For example, Thymogen (Glu-Trp) is a dipeptide bioregulator primary studied for its general immunomodulatory effects on T-cell differentiation, whereas Bronchogen demonstrates a tissue-specific affinity for bronchial epithelial and smooth muscle expression profiles. Similarly, Vilon (Lys-Glu) exhibits potent immunoregulatory and anti-fibrotic activity in systemic connective tissue models, while Epitalon (Ala-Glu-Asp-Gly) is studied primarily for telomerase activation and neuroendocrine regulation. Researchers exploring complex inflammatory models frequently cross-reference these bioregulators within our full catalog of research peptides to design multi-targeted in vitro protocols.
The synthesis of short peptides like Bronchogen requires precision chemistry to prevent sequence truncation, racemization, or residual solvent contamination. PX1 Research utilizes advanced Solid-Phase Peptide Synthesis (SPPS) protocols under stringent ISO 9001 and GMP-compliant operational standards. Acidic residues such as Asp and Glu demand specialized protecting groups (e.g., OtBu) and precise cleavage chemistry to prevent side reactions during synthesis.
Following cleavage and deprotection, crude Bronchogen undergoes multi-stage purification using preparative High-Performance Liquid Chromatography (HPLC). This process isolates the target Ala-Asp-Glu-Leu sequence from incomplete peptide fragments and chemical reagents, yielding a final compound purity exceeding 98.0%.
Our manufacturing infrastructure emphasizes batch-to-batch consistency. Each production run is assigned a unique lot number linked to comprehensive synthesis logs, raw material origin records, and analytical data sheets. This level of traceability ensures that researchers receive identical chemical properties across long-term, longitudinal studies.
Analytical rigor is essential when sourcing compounds for delicate cell culture and animal studies. PX1 Research subjects every lot of Bronchogen to independent, third-party laboratory verification conducted by accredited ISO 17025 facilities.
Purity is verified using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) coupled with ultraviolet (UV) detection. Chromatograms must display a single sharp peak corresponding to Ala-Asp-Glu-Leu with a relative peak area of >= 98.0%. Molecular identity is simultaneously confirmed via Electrospray Ionization Mass Spectrometry (ESI-MS), verifying the exact monoisotopic mass of the peptide (theoretical mass approx. 432.42 g/mol).
Crucially for pulmonary and airway hyperresponsiveness research, endotoxin levels are quantified using the Limulus Amebocyte Lysate (LAL) chromogenic assay. Because lipopolysaccharide (LPS) contamination can independently induce severe airway inflammation and obscure experimental findings, PX1 enforces a strict upper endotoxin threshold of < 0.05 EU/mg. Complete, unedited COAs are publicly accessible for every available batch via our PX1 research library hub.
Proper handling and storage of synthetic Bronchogen are necessary to preserve peptide stability and prevent catalytic degradation. Bronchogen is supplied as a lyophilized (freeze-dried) sterile powder in sealed glass vials.
For laboratory reconstitution, researchers should use sterile, endotoxin-free water for injection or sterile phosphate-buffered saline (PBS, pH 7.4). Due to the presence of hydrophobic and acidic amino acids, gently agitate the vial without vigorous vortexing to prevent protein denaturation or foaming. Reconstitution should always occur under a laminar flow hood using aseptic technique.
Lyophilized Bronchogen remains stable at -20°C for up to 24 months, or at -80°C for extended archival storage. Once reconstituted into liquid solution, aliquots should be stored at -20°C or -80°C to minimize degradation from repeated freeze-thaw cycles. Working solutions kept at 4°C should be utilized within 7 to 14 days to ensure theoretical activity.
Research timelines require reliable delivery schedules and uncompromised supply chains. PX1 Research manages domestic fulfillment centers in California and Arizona, facilitating temperature-monitored shipping across the United States.
Orders placed before 12:00 PM PST Monday through Friday are processed for same-day dispatch. Lyophilized peptides are packaged with protective cold packs and impact-resistant thermal shielding to shield the peptide matrix from environmental temperature spikes during transport.
By avoiding foreign re-shippers and unverified third-party importers, PX1 eliminates customs delays, transit degradation, and uncertainty surrounding product origin. Principal investigators and laboratory managers can depend on consistent product availability and rapid delivery.
High-throughput screening assays, non-human primate research, and large-cohort animal trials often demand bulk quantities of high-purity peptides with unified lot controls. PX1 Research provides specialized procurement programs tailored to academic labs, biotechnology entities, and institutional facilities.
Through our dedicated wholesale laboratory accounts, research institutions gain access to custom synthesis lot sizes, dedicated analytical testing suites, and volume-adjusted pricing models. Our technical support team works directly with laboratory procurement officers to provide custom packaging, specialized vial configurations, and pre-reserved batch reservations for ongoing research initiatives.
What is Bronchogen used for in laboratory research?
Bronchogen (Ala-Asp-Glu-Leu) is a synthetic tetrapeptide used strictly in preclinical and in vitro laboratory research to study bronchial tissue remodeling, epithelial barrier integrity, chromatin binding, and airway hyperresponsiveness signaling pathways.
How does PX1 Research verify Bronchogen peptide purity?
Every batch of Bronchogen undergoes third-party analytical testing at an accredited ISO 17025 laboratory using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm purity >= 98%, and Electrospray Ionization Mass Spectrometry (ESI-MS) to confirm molecular weight.
What is the endotoxin limit for PX1 Research Bronchogen?
PX1 Research enforces a strict endotoxin limit of < 0.05 EU/mg for Bronchogen, verified via chromogenic Limulus Amebocyte Lysate (LAL) testing, preventing non-specific inflammatory responses in delicate cell culture and animal models.
What solvent is recommended for reconstituting Bronchogen in vitro?
For cell culture and tissue assays, Bronchogen should be reconstituted using sterile, endotoxin-free water or sterile phosphate-buffered saline (PBS, pH 7.4) under aseptic conditions within a laminar flow hood.
How should lyophilized and reconstituted Bronchogen be stored?
Lyophilized powder should be stored at -20°C or -80°C for long-term stability. Once reconstituted, solution aliquots should be frozen at -20°C or -80°C to avoid repeated freeze-thaw cycles. Reconstituted solution stored at 4°C should be used within 7–14 days.
Is PX1 Research Bronchogen manufactured in the United States?
Yes. PX1 Research manufactures all research peptides in US-based, GMP-compliant facilities and dispatches orders from fulfillment hubs in California and Arizona.
Can Bronchogen be obtained in bulk quantities for large animal studies?
Yes. Institutional researchers can establish a wholesale laboratory account to secure custom lot sizes, reserved batch quantities, and unified analytical documentation for large-scale preclinical trials.
Where can I view the Certificate of Analysis (COA) for my Bronchogen lot?
Lot-specific COAs detailing HPLC chromatograms, mass spectra, and endotoxin assay results are accessible on the PX1 Research website or by contacting technical support with your batch number.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.